Before the COVID-19 pandemic, most investors likely hadn't heard of (NASDAQ: MRNA). At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue and no commercially available products.

What followed was a wild ride in which Moderna burst into the public consciousness as it developed and began selling one of the COVID-19 vaccines, putting the company and its mRNA technology at the forefront of investors' minds. Nearly four years later, the company is in a curious spot as it still has only one commercially available product.

However, Moderna is developing a robust pipeline that could propel the company for the foreseeable future. Is that pipeline strong enough to warrant buying the stock now, or should investors sit on the sidelines and wait? Let's dig in and see.

Continue reading

Source Fool.com